CRLS1
Gene Information
- Official Symbol: CRLS1
- Official Name: cardiolipin synthase 1
- Aliases and Previous Symbols: N/A
- Entrez ID: 54675
- UniProt: Q9UJA2
- Interactions: BioGRID
- PubMed articles: Open PubMed
- OMIM: Open OMIM
Function Summary
- Entrez Summary: N/A
- UniProt Summary: Catalyzes the synthesis of cardiolipin (CL) (diphosphatidylglycerol) by specifically transferring a phosphatidyl group from CDP-diacylglycerol to phosphatidylglycerol (PG). CL is a key phospholipid in mitochondrial membranes and plays important roles in maintaining the functional integrity and dynamics of mitochondria under both optimal and stress conditions. {ECO:0000269|PubMed:16547353, ECO:0000269|PubMed:16678169}.
Pfam Domains GO Terms
Pfam Domains
| CDP-OH P transf |
GO Terms
| CDP-diacylglycerol-phosphatidylglycerol phosphatidyltransferase activity |
| response to phosphatidylethanolamine |
| cardiolipin synthase activity |
| 2-acylglycerol-3-phosphate O-acyltransferase activity |
| response to L-phenylalanine derivative |
| response to thyroxine |
| cardiolipin biosynthetic process |
| phosphatidylglycerol biosynthetic process |
| cardiolipin metabolic process |
| 1-acylglycerol-3-phosphate O-acyltransferase activity |
| phosphatidylglycerol acyl-chain remodeling |
| response to thyroid hormone |
| phosphatidylglycerol metabolic process |
| response to amino acid |
| response to organophosphorus |
| glycerophospholipid biosynthetic process |
| glycerolipid biosynthetic process |
| phospholipid biosynthetic process |
| glycerophospholipid metabolic process |
| response to acid chemical |
| phospholipid metabolic process |
| glycerolipid metabolic process |
| mitochondrial inner membrane |
| organophosphate biosynthetic process |
| lipid biosynthetic process |
| response to lipid |
| organophosphate metabolic process |
| response to hormone |
| response to organic cyclic compound |
| cellular lipid metabolic process |
| response to organonitrogen compound |
| response to drug |
| response to nitrogen compound |
| lipid metabolic process |
| mitochondrion |
| response to endogenous stimulus |
| response to oxygen-containing compound |
CRISPR Data
Compound Hit Most Correlated Genes in Chemogenomics Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Compound Hit
Most Correlated Genes in Chemogenomics
| Gene | Correlation |
|---|---|
| TRIAP1 | 0.717 |
| TAZ | 0.715 |
| ROMO1 | 0.712 |
| OPA1 | 0.657 |
| TAMM41 | 0.62 |
| PMM2 | 0.613 |
| SLC25A26 | 0.612 |
| TIMM13 | 0.607 |
| RPE | 0.584 |
| DNLZ | 0.583 |
| SRP14 | 0.576 |
| HCCS | 0.562 |
| APAF1 | 0.56 |
| CYCS | 0.557 |
| HARS | 0.557 |
| PARL | 0.537 |
| SUPV3L1 | 0.524 |
| DPAGT1 | 0.52 |
| UAP1 | 0.513 |
| DOHH | 0.509 |
| ALG5 | 0.508 |
| BAK1 | 0.505 |
| TIMM8B | 0.502 |
| THG1L | 0.498 |
| MRPS14 | 0.496 |
| MRPS6 | 0.496 |
| ALG1 | 0.491 |
| UBE2G2 | 0.49 |
| DAP3 | 0.489 |
| TIMM17A | 0.489 |
| CASP9 | 0.488 |
| TRMT10A | 0.484 |
| RPTOR | 0.483 |
| AASDHPPT | 0.482 |
| COQ5 | 0.48 |
| ENO1 | 0.479 |
| KIAA0391 | 0.478 |
| MRPL21 | 0.477 |
| ALG6 | 0.475 |
| MRPS18A | 0.474 |
| HSPD1 | 0.473 |
| PDSS1 | 0.472 |
| GFPT1 | 0.472 |
| TIMM23B | 0.471 |
| TKT | 0.471 |
| BAP1 | 0.468 |
| VDAC2 | 0.468 |
| COQ3 | 0.467 |
| RPUSD4 | 0.464 |
| HSD17B10 | 0.463 |
| ATP2A2 | 0.459 |
| MRPS16 | 0.459 |
| CBFB | 0.458 |
| TPI1 | 0.458 |
| PNPT1 | 0.456 |
| FAM210A | 0.455 |
| PLAA | 0.455 |
| MRPL23 | 0.453 |
| SEC62 | 0.453 |
| SERF2 | 0.451 |
| PPP2R3C | 0.448 |
| MFN1 | 0.446 |
| PISD | 0.446 |
| ATP5J | 0.445 |
| GMPPB | 0.445 |
| PGM3 | 0.444 |
| ZFP91 | 0.441 |
| PAM16 | 0.44 |
| MRPS9 | 0.44 |
| ATP5A1 | 0.44 |
| MRPS33 | 0.439 |
| MRPS34 | 0.438 |
| PPA2 | 0.438 |
| MEAF6 | 0.437 |
| MRPL47 | 0.436 |
| HARS2 | 0.436 |
| GPI | 0.436 |
| DARS2 | 0.435 |
| GFM1 | 0.435 |
| COQ6 | 0.434 |
| VARS2 | 0.434 |
| ATXN10 | 0.434 |
| MRPS5 | 0.434 |
| PPCS | 0.434 |
| YARS2 | 0.433 |
| MRP63 | 0.433 |
| COX16 | 0.432 |
| WBSCR16 | 0.429 |
| PARS2 | 0.429 |
| KDSR | 0.428 |
| WDR24 | 0.428 |
| TMEM41B | 0.427 |
| UBE2K | 0.427 |
| THOC6 | 0.427 |
| ENY2 | 0.427 |
| BRWD1 | 0.426 |
| SLMO2 | 0.426 |
| TRNT1 | 0.425 |
| DHRSX | 0.425 |
| ATP5B | 0.423 |
| GFER | 0.422 |
| VMP1 | 0.422 |
| RNMT | 0.422 |
| BCS1L | 0.421 |
| TBCA | 0.42 |
| ELF2 | 0.419 |
| MTOR | 0.418 |
| PGGT1B | 0.418 |
| TUFM | 0.418 |
| UHRF1 | 0.418 |
| MRPL15 | 0.417 |
| ALG13 | 0.417 |
| DHPS | 0.417 |
| SRD5A3 | 0.417 |
| UBE2M | 0.416 |
| MRPL36 | 0.416 |
| MRPL53 | 0.415 |
| UBE2J1 | 0.415 |
| DAD1 | 0.415 |
| DHX30 | 0.415 |
| ATP5C1 | 0.413 |
| GTF3C3 | 0.413 |
| GTF3C6 | 0.413 |
| SARS2 | 0.413 |
| CSNK2B | 0.412 |
| ATP5D | 0.412 |
| RPIA | 0.412 |
| NAE1 | 0.409 |
| UTP23 | 0.409 |
| DIABLO | 0.409 |
| PGLS | 0.407 |
| PGS1 | 0.406 |
| RBFA | 0.406 |
| SUV420H1 | 0.406 |
| AARS | 0.405 |
| LSM10 | 0.405 |
| ATP5O | 0.404 |
| RTCB | 0.404 |
| PGP | 0.404 |
| NSD1 | 0.404 |
| TIMM44 | 0.403 |
| TIMM8A | 0.402 |
| FGFR1OP | 0.401 |
| EXOC4 | 0.401 |
| EIF3F | 0.4 |
| SELRC1 | 0.4 |
| CHCHD4 | 0.4 |
Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Global Fraction of Cell Lines Where Essential: 98/739
| Tissue | Fraction Of Cell Lines Where Essential |
|---|---|
| 1290807.0 | 0/1 |
| 909776.0 | 0/1 |
| bile duct | 4/28 |
| blood | 3/28 |
| bone | 4/26 |
| breast | 6/33 |
| central nervous system | 8/56 |
| cervix | 0/4 |
| colorectal | 3/17 |
| esophagus | 3/13 |
| fibroblast | 1/1 |
| gastric | 2/16 |
| kidney | 3/21 |
| liver | 3/20 |
| lung | 11/75 |
| lymphocyte | 4/16 |
| ovary | 1/26 |
| pancreas | 6/24 |
| peripheral nervous system | 0/16 |
| plasma cell | 1/15 |
| prostate | 0/1 |
| skin | 3/24 |
| soft tissue | 2/9 |
| thyroid | 0/2 |
| upper aerodigestive | 1/22 |
| urinary tract | 3/29 |
| uterus | 1/5 |
Essentiality in NALM6
- Essentiality Rank: 322
- Expression level (log2 read counts): 5.61
Expression Distribution
CRLS1 Expression in NALM6 Cells: 5.61